
Domain Therapeutics enters into a new collaboration agreement with Pfizer Inc. to profile signaling pathways of GPCRs across multiple diseases
French biotech company will use its bioSens-All proprietary technology to correlate impact of GPCR mutations on signaling pathways Results may